Acrux Limited (ASX: ACR) - Share Price
- Current share price for ACR : $0.011
Acrux Limited (ACR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a specialty pharmaceutical company with a track record of developing, registering and commercialising a portfolio of topically applied generic pharmaceutical products with a primary focus on the US market.
ACR General Information +
| ASX Code | ACR |
| Website | http://www.acrux.com.au |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 6 |
| ACR Share Price | $0.011 |
| Day High | $0.011 |
| Day Low | $0.011 |
| Last Close | $0.011 |
| ACR Share Price Movement | - ( No change ) |
Prices as at 12:20, 7 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Acrux Limited (ACR) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 6¢ | 100% | 18 Aug 2015 | 3 Sep 2015 | - | - | - |
| HFResult | 8¢ | 100% | 4 Sep 2014 | 22 Sep 2014 | - | - | - |
| Result | 12¢ | 0% | 25 Feb 2014 | 20 Mar 2014 | - | - | - |
See all dividends from Acrux Limited (ACR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Acrux Limited (ACR) price-sensitive announcements
ACR - Investor Presentation - Female Testosterone for HSDD
The investor presentation by Acrux Limited at the Bioshares Biotech Summit on 6 August 202
Acrux Limited (ACR)
6 Aug 2026 | 9:02 AM
6 Aug 2026 | 9:02 AM
ACR - Quarterly Activities/Appendix 4C Cash Flow Report
The document is Acrux Limited's Quarterly Activities Report and Appendix 4C Cash Flow Repo
Acrux Limited (ACR)
31 Jul 2026 | 10:07 AM
31 Jul 2026 | 10:07 AM
ACR - Update - Licensing Lenzetto for Australia for AUD5.4m
Acrux Limited announced the licensing of Lenzetto® for the Australian market with a total
Acrux Limited (ACR)
29 May 2026 | 12:19 PM
29 May 2026 | 12:19 PM
ACR - Acrux licenses Lenzetto for Australian market for AUD5.4m
Acrux Limited announced an amended licensing agreement with Gedeon Richter Plc for the dis
Acrux Limited (ACR)
28 May 2026 | 9:04 AM
28 May 2026 | 9:04 AM
Acrux Limited (ACR) Recent ASX Announcements
ACR Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$5.95 | -$1.70 | -15.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$5.80 | -$2.00 | 1,233.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$0.44 | -$0.20 | -95.70% | 0.00 | 0.00 | 0.00% | 0.0% |
ACR Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Acrux Limited (ACR) | $6M | -0.1550 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Clarity Pharmaceuticals Ltd (CU6) | $1,007M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,743M | -0.7857 | 0.0743 | 1.2000 | 92.9953 | 86.5600 | 39.3455 | 0.00% | 0.00% | 0.00% |
ACR Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 4.40 | 0.00 |
| Market | 0.61 | 18.10 | 1.66 | 1.04 |
| Sector | 0.49 | 33.70 | 2.45 | 2.65 |
ACR Directors
| Name | Position | Start Date |
|---|---|---|
| Mr John Warmbrunn | Chief Executive Officer, Managing Director | 1 Jun 2025 |
| Mr Ross Dobinson | Non-Executive Chairman, Non-Executive Director | 19 Mar 1998 |
| Dr Geoffrey Edward Duncan Brooke | Non-Executive Director | 1 Jun 2016 |
| Dr Timothy Oldham | Non-Executive Director | 1 Oct 2013 |
| Mr Donald Charles Brumley | Non-Executive Director | 4 Jun 2021 |
Acrux Limited (ACR) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 4 Mar 2025 | DOBINSON, Ross | Issued | Direct Shares | 571,428 | $0.035 | $20,000.000 |
| 13 Feb 2025 | KOTSANIS, Michael | Issued | Direct Shares | 857,142 | $0.035 | $30,000.000 |
| 13 Feb 2025 | OLDHAM, Timothy | Issued | Indirect Shares | 285,714 | $0.035 | $10,000.000 |
See all changes in directors' interest & trades for Acrux Limited (ACR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ACR Management
| Name | Position |
|---|---|
| Joanna Johnson | Chief Financial Officer,Company Secretary |
| Felicia Colagrande | Product Development and Technical Affairs Director |
| Mark Hyman | Project and Technical Development Director |
ACR Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Acrux Limited (ACR). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 37,561,419 (9.18%) | Phillip Asset Management Ltd |
ACR Calendar of Events
| Date | Event |
|---|---|
| 24 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
